panitumumab
takeda,amgen
['triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
 phiii triplete ras/braf wt #mcrc (88% l-sided) #1l folfoxiri-pmab (2400 5-fu, 150 irino) no sig diff in primary endpt orr or r0 rate vs folfox-pmab = when use of targeted agents in molecularly selected pop no benefit of intensification of chemo #asco22 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope